Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Chemotherapy in Treatment Naïve AML
NCT03709758Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2018
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose (Induction) at 2 years and Maximum Tolerated Dose (Consolidation) at 2 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03709758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709758.